Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services.

Clinical Sarcoma Research Pub Date : 2016-07-11 eCollection Date: 2016-01-01 DOI:10.1186/s13569-016-0052-4
Susie Bae, Philip Crowe, Raghu Gowda, Warren Joubert, Richard Carey-Smith, Paul Stalley, Jayesh Desai
{"title":"Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services.","authors":"Susie Bae,&nbsp;Philip Crowe,&nbsp;Raghu Gowda,&nbsp;Warren Joubert,&nbsp;Richard Carey-Smith,&nbsp;Paul Stalley,&nbsp;Jayesh Desai","doi":"10.1186/s13569-016-0052-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is a paucity of data on the current management of patients with advanced soft tissue sarcoma (STS) in the Australian health care setting. This study utilised the Australian sarcoma database to evaluate the patterns of care delivered to patients with advanced STS at Australian sarcoma services.</p><p><strong>Methods: </strong>Prospectively collected data from six sarcoma centres in Australia were sourced to identify patients diagnosed with advanced STS between 1 January 2010 and 31 December 2012. Descriptive statistics were analysed for patient demographics, clinicopathological characteristics and treatment patterns. Overall survival was estimated using the Kaplan-Meier product limit method.</p><p><strong>Results: </strong>Of 253 patients with advanced STS, four major STS subtypes were identified: undifferentiated pleomorphic sarcoma (23 %), leiomyosarcoma (17 %), liposarcoma (14 %), and synovial sarcoma (8 %); with the rest grouped as \"other STS\" (38 %). Approximately one-third of patients received palliative systemic therapy with the most common first-line therapy being doxorubicin alone (50 %). A small percentage of patients participated in clinical trials (20 %). Palliative radiotherapy was utilised mostly for treatment of symptomatic distant metastases and one-third of patients underwent metastasectomy, most commonly for pulmonary metastases. The median overall survival (OS) in this series was 18 months and no significant difference in OS was observed across different STS histological subtypes.</p><p><strong>Conclusions: </strong>This is the first detailed study outlining patterns of care for Australian patients with advanced STS managed at sarcoma services. These data highlight a particular area of weakness in the lack of clinical trials for sarcoma patients and also serve as an important reference point for understanding how practice may change over time as treatment options evolve.</p>","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"6 ","pages":"11"},"PeriodicalIF":0.0000,"publicationDate":"2016-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-016-0052-4","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Sarcoma Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13569-016-0052-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 16

Abstract

Background: There is a paucity of data on the current management of patients with advanced soft tissue sarcoma (STS) in the Australian health care setting. This study utilised the Australian sarcoma database to evaluate the patterns of care delivered to patients with advanced STS at Australian sarcoma services.

Methods: Prospectively collected data from six sarcoma centres in Australia were sourced to identify patients diagnosed with advanced STS between 1 January 2010 and 31 December 2012. Descriptive statistics were analysed for patient demographics, clinicopathological characteristics and treatment patterns. Overall survival was estimated using the Kaplan-Meier product limit method.

Results: Of 253 patients with advanced STS, four major STS subtypes were identified: undifferentiated pleomorphic sarcoma (23 %), leiomyosarcoma (17 %), liposarcoma (14 %), and synovial sarcoma (8 %); with the rest grouped as "other STS" (38 %). Approximately one-third of patients received palliative systemic therapy with the most common first-line therapy being doxorubicin alone (50 %). A small percentage of patients participated in clinical trials (20 %). Palliative radiotherapy was utilised mostly for treatment of symptomatic distant metastases and one-third of patients underwent metastasectomy, most commonly for pulmonary metastases. The median overall survival (OS) in this series was 18 months and no significant difference in OS was observed across different STS histological subtypes.

Conclusions: This is the first detailed study outlining patterns of care for Australian patients with advanced STS managed at sarcoma services. These data highlight a particular area of weakness in the lack of clinical trials for sarcoma patients and also serve as an important reference point for understanding how practice may change over time as treatment options evolve.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
晚期软组织肉瘤患者的护理模式:来自澳大利亚肉瘤服务的经验。
背景:目前澳大利亚卫生保健机构对晚期软组织肉瘤(STS)患者的管理数据缺乏。本研究利用澳大利亚肉瘤数据库来评估澳大利亚肉瘤服务部门对晚期STS患者的护理模式。方法:前瞻性收集来自澳大利亚六个肉瘤中心的数据,以确定2010年1月1日至2012年12月31日期间诊断为晚期STS的患者。描述性统计分析患者人口统计学、临床病理特征和治疗模式。用Kaplan-Meier积极限法估计总生存期。结果:253例晚期STS患者中,鉴定出4种主要STS亚型:未分化多形性肉瘤(23%)、平滑肌肉瘤(17%)、脂肪肉瘤(14%)和滑膜肉瘤(8%);其余为“其他化粪池系统”(38%)。大约三分之一的患者接受了姑息性全身治疗,最常见的一线治疗是单独使用阿霉素(50%)。一小部分患者参加了临床试验(20%)。姑息性放疗主要用于治疗有症状的远处转移,三分之一的患者接受了转移切除术,最常见的是肺转移。该系列研究的中位总生存期(OS)为18个月,不同STS组织学亚型的OS无显著差异。结论:这是第一项详细的研究,概述了澳大利亚晚期STS患者在肉瘤服务中心的护理模式。这些数据突出了缺乏肉瘤患者临床试验这一特定领域的弱点,也为理解实践如何随着治疗方案的发展而变化提供了重要的参考点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊介绍: Clinical Sarcoma Research considers for publication articles related to research on sarcomas, including both soft tissue and bone. The journal publishes original articles and review articles on the diagnosis and treatment of sarcomas along with new insights in sarcoma research, which may be of immediate or future interest for diagnosis and treatment. The journal also considers negative results, especially those from studies on new agents, as it is vital for the medical community to learn whether new agents have been proven effective or ineffective within subtypes of sarcomas. The journal also aims to offer a forum for active discussion on topics of major interest for the sarcoma community, which may be related to both research results and methodological topics.
期刊最新文献
Partial response to erlotinib in a patient with imatinib-refractory sacral chordoma. Locally recurrent extraskeletal myxoid chondrosarcoma of the shoulder: a case of complete neoadjuvant radiotherapy response. The role of prognostic nutritional index in the management of pulmonary sarcomatoid carcinoma. Ifosfamide-induced encephalopathy: the EEG with frontal intermittent delta activity, and rapid resolution with methylene blue: A case report. Simultaneous diagnosis of liver PEComa in a family with known Li-Fraumeni syndrome: a case report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1